PF 04671536 hydrochloride

Pricing Availability Delivery Time Qty
Cat.No. 6024 - PF 04671536 hydrochloride | C14H18N8OS.HCl | CAS No. 1305116-67-9
Description: Potent and selective PDE8B/8A inhibitor
Chemical Name: 5-Methyl-3-[[(2R)-4-(2-thiazolylmethyl)-2-morpholinyl]methyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-7-amine hydrochloride
Purity: ≥98% (HPLC)

Biological Activity

Potent and selective PDE8B/8A inhibitor ( IC50 values are 1.3 and 1.9 nM, respectively). Exhibits selectivity for PDE8A/B over other PDEs (IC50 values are >10 μM) and a range of other targets. Increases glucose-dependent insulin secretion from human pacreatic islet cells. Orally bioavailable.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc

Technical Data

M. Wt 382.87
Formula C14H18N8OS.HCl
Storage Desiccate at RT
Purity ≥98% (HPLC)
CAS Number 1305116-67-9
Smiles CC1=NC(N)=C2N=NN(C2=N1)C[C@H]3CN(CCO3)CC4=NC=CS4.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 38.29 100
water 7.66 20mM with gentle warming

Preparing Stock Solutions

The following data is based on the product molecular weight 382.87. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.61 mL 13.06 mL 26.12 mL
5 mM 0.52 mL 2.61 mL 5.22 mL
10 mM 0.26 mL 1.31 mL 2.61 mL
50 mM 0.05 mL 0.26 mL 0.52 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Safety Datasheet


References are publications that support the products' biological activity.

DeNinno et al (2012) Discovery of triazolopyrimidine-based PDE8B inhibitors: exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes. Bioorg.Med.Chem.Lett. 22 5721 PMID: 22858141

If you know of a relevant reference for PF 04671536 hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Phosphodiesterase Inhibitors

Keywords: PF 04671536 hydrochloride, supplier, PF04671536, hydrochloride, diabetes, phosphodiesterase, 8A, 8B, PDE, potent, selective, orally, bioavailable, antidiabetics, inhibitors, inhibits, Phosphodiesterases, Phosphodiesterases, Tocris Bioscience

Citations for PF 04671536 hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for PF 04671536 hydrochloride. Do you know of a great paper that uses PF 04671536 hydrochloride from Tocris? If so please let us know.

Reviews for PF 04671536 hydrochloride

There are currently no reviews for this product. Be the first to review PF 04671536 hydrochloride and earn rewards!

Have you used PF 04671536 hydrochloride?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area


Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.